Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Return on Sales (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Return on Sales for 17 consecutive years, with 0.04% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales rose 16.0% to 0.04% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.44%, a 29.0% decrease, with the full-year FY2025 number at 0.44%, down 29.0% from a year prior.
  • Return on Sales was 0.04% for Q4 2025 at Myriad Genetics, up from 0.13% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.15% in Q3 2021 to a low of 1.55% in Q2 2025.
  • A 5-year average of 0.23% and a median of 0.15% in 2023 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: surged 198bps in 2021, then plummeted -138bps in 2025.
  • Myriad Genetics' Return on Sales stood at 0.05% in 2021, then plummeted by -403bps to 0.24% in 2022, then soared by 33bps to 0.16% in 2023, then decreased by -27bps to 0.2% in 2024, then surged by 81bps to 0.04% in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Return on Sales are 0.04% (Q4 2025), 0.13% (Q3 2025), and 1.55% (Q2 2025).